UNITAID approves US$ 30 million for innovative project to roll out ground-breaking tuberculosis test at reduced cost

Xpert, once introduced and widely scaled-up, is expected to dramatically reduce the diagnostic gaps for tuberculosis, in particular in its multi-drug resistant form, or associated with an HIV infection.

Read More →

Transforming the HIV/TB response: Defining the next 10 years

International consultation convened in conjunction with AIDS 2012
Date: 21 July 2012
Time: 09:00 – 17:00
Location: Rm. 202, Georgetown Law, 600 New Jersey Ave., NW, McDonough Hall, Washington, DC 20001

Read More →

Round table discussion: Activist engagement and community involvement in TB research

3rd Annual South African TB Conference, Durban 2012
Date: 14 June 2012
Time: 14h00 – 15h30
Location: Hall 3B

Read More →

Tackling TB: Expand access to and improve affordability of diagnostics and treatment

Statement by the Treatment Action Campaign, SECTION27, Médecins Sans Frontières and Oxfam.

Read More →

Janssen: Response to TB CAB letter

Janssen's response to TB CAB letter regarding pharmacokinetic studies, paediatric studies, and compassionate use of bedaquiline.

Read More →

World Health Organization sets out route map for scale up of treatment as prevention

WHO is working with countries to identify opportunities for expansion of treatment in line with its 2010 guidelines, which recommended treatment for all people living with HIV with CD4 cell counts below 350, all infants below the age of 2, and for everyone with TB and HIV or hepatitis B and HIV coinfection.

Read More →

Russia: Fight against TB plagued by shortfalls

Russia currently ranks third by the number of multidrug-resistant TB cases worldwide after China and India, countries with vastly larger populations.

Read More →

Novel agent works against resistant TB

The investigational drug delamanid may help combat multidrug-resistant tuberculosis, results of a phase II trial indicate.

Read More →

South Africa: Changes to ART guidelines

All HIV-positive TB patients, with immediate effect, are initiated on ART, irrespective of CD4 count.

Read More →

TB CAB: Open letters to drug companies and FDA on delanamid and bedaquiline

Open letters to Otsuka, Janssen Pharmaceutical Companies of Johnson & Johnson, Food and Drug Administration and European Medicines Agency.

Read More →

Page 85 of 94 · Total posts: 10

←First 84 85 86 Last→